Identification of Novel Mutations in Patients Affected by Gaucher Disease
Authors:
- Monia AnaniaMAMonia Anania
- Miriam GiacomarraMGMiriam Giacomarra
- Annalisa D’erricoADAnnalisa D’errico
- Massimo MaranoMMMassimo Marano
- Immacolata TartaglioneITImmacolata Tartaglione
- Marco SpadaMSMarco Spada
- Veronica PagliardiniVPVeronica Pagliardini
- Maria Rosaria De PaolisMPMaria Rosaria De Paolis
- Gaetano GiuffridaGGGaetano Giuffrida
- Giulia DuroGDGiulia Duro
- Tiziana Di ChiaraTCTiziana Di Chiara
- Daniele FrancofonteDFDaniele Francofonte
Open Access
- 21 April 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3918
Abstract
Gaucher disease is an autosomal recessive disorder caused by dysfunction of the enzyme glucocerebrosidase. The enzyme deficiency is mainly due to mutations in the GBA1 gene, and it is responsible for the accumulation of glucosylceramide within the lysosomes of monocyte macrophage-derived cells; causing the associated symptomatology. In this paper, we describe six new mutations identified in the GBA1 gene, which, in combination with other mutations already documented, lead to absent or reduced glucocerebrosidase activity, resulting in pathological accumulation of the specific substrate and the clinical manifestations associated with Gaucher disease. We have identified three mutations (c.1578_1581dup, c.1308dup, and Y492X) that determine the formation of a premature stop codon in the translation process and three missense mutations (C342F, M280L, and Q247R) that lead to amino acid changes in proteins, resulting in decreased glucocerebrosidase activity. These mutations were never observed in our group of healthy control subjects > 1500 individuals. The patients examined had several clinical manifestations, which included hepatosplenomegaly and bone and hematologic involvement; considering the absence of enzyme activity, this suggests that the new mutations described here are associated with type I Gaucher disease. The identification of new mutations in patients with symptoms referable to Gaucher disease increases the molecular knowledge related to the GBA1 gene and offers to clinicians significant support for the accurate diagnosis of the pathology.Keywords
This publication has 32 references indexed in Scilit:
- Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MSClinical Biochemistry, 2021
- Lysosome and Inflammatory Defects in GBA1‐Mutant Astrocytes Are Normalized by LRRK2 InhibitionMovement Disorders, 2020
- Gaucher Disease in Bone: From Pathophysiology to PracticeJournal of Bone and Mineral Research, 2019
- Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East ItalyJournal of Inherited Metabolic Disease, 2017
- Gaucher disease2013
- A reappraisal of Gaucher disease—diagnosis and disease management algorithmsAmerican Journal of Hematology, 2010
- Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)Human Mutation, 2008
- Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among Hematologists–Oncologists and an opportunity for early diagnosis and interventionAmerican Journal of Hematology, 2007
- Three unique base pair changes in a family with Gaucher diseaseHuman Genetics, 1991
- Prevalent and rare mutations among Gaucher patientsGene, 1990